IgD is a surface immunoglobulin, which is coexpressed with IgM on >90% of mature B cells, but its levels in serum are extremely low compared to those of IgM. Its role as a surface receptor has been reemphasized by our recent findings that IgD receptors are induced on helper T cells by exposure to IgD and that such cells have immunoaugmenting properties. The present study shows that crosslinking of soluble IgD or of monomeric cell surface IgD is required and sufficient for the induction of T cells bearing receptors for IgD, both in vivo and in vitro. Effective IgD crosslinking in this respect can be obtained with antigen or with heterologous and immunogenic as well as nonimmunogenic allotype-specific anti-IgD. These results reinforce the concept that the induction of T cells bearing receptors for IgD is an integral component of the normal immune response.
Recent studies in our laboratory have demonstrated the existence of helper T cells bearing receptors for IgD (T8) (1) . This observation grew out of our earlier studies in which mice that bore the IgD-secreting TEPC-1017 or TEPC-1033 myeloma were found to generate significantly increased antibody responses to various antigens (2) . Investigation of the cellular basis for this immunoaugmenting effect of IgD revealed that the elevated serum IgD levels in such mice stimulated the appearance of a significantly increased number of T cells that were capable of forming rosettes with IgD-coated sheep erythrocytes (SRBC) (3) . Results from cell transfer studies confirmed that T cells exposed to IgD myeloma protein either in vivo or in vitro have a significant immunoaugmenting effect on antibody production in recipients (3, 4) .
Various methods of inducing TS cells were investigated. It was found that IgD receptors can also be induced in vivo by injection of antigen (1) or lymphokines, including interleukin 2 (IL-2) and interferon y (5) . Exposure of helper T cells to such lymphokines in vitro also causes the expression of IgD receptors (5) . In addition, resting T-cell clones of helper phenotype (L3T4+, Lyt-1', Lyt-2-), grown in the absence of IL-2, responded with increased IgD-receptor expression following overnight exposure to IgD or recombinant IL-2 (5). This effect was also seen when T-cell clones were stimulated with antigen in the absence of exogenously supplied IgD or IL-2, presumably as a result of autocrine secretion of lymphokines in response to antigen (5) .
Our findings that both T-dependent and T-independent antigens cause a small but significant increase in the frequency of TS cells within 5 days of antigen injection suggest that crosslinking of B-cell surface IgD by physiological stimuli induces TS cells. The present studies were carried out to explore further the role of IgD crosslinking in IgDreceptor induction. The findings show that T cells are induced to express receptors for IgD following exposure to IgD aggregated by anti-IgD. In addition, taking advantage of the availability of an IgD-secreting B-cell hybridoma, (14) was isolated from ascites fluid by sequential (NH4)2SO4 precipitation, DEAE-cellulose ion-exchange chromatography, and Sephadex G-200 gel filtration (13 In Vivo Induction of TS Cells by Goat Anti-IgD Antiserum. Our finding that crosslinking of IgD is necessary for induction of TS cells in vitro suggested that a similar stimulus might also be capable of inducing such cells in vivo. Preliminary support for this hypothesis was provided in previously reported studies (1), which showed that following injection with antigen a small but significant increase in the incidence of TS cells is observed. In order to confirm if such crosslinking in vivo could also induce T8 cells, we injected mice with affinity-purified goat anti-IgD and followed the kinetics of induction of TS cells in their spleens. The results show that, 24 hr following injection with goat anti-IgD, there is a significant increase in the frequency of splenic IgD-RFC (Fig. 1) . As expected, cell fractionation studies confirmed that the splenic T cells were responsible for rosette formation with the IgD-coated indicator cells. It has been reported that treatment with goat anti-IgD results in polyclonal activation of the B-cell population (11, (19) (20) (21) . Analysis of the cellular basis for this effect established that such activation is largely due to B-cell stimulation by the combination of anti-IgD and lymphokines produced by T cells, which are responding to the goat immunoglobulin presented to them by the anti-IgD-coated B cells (22) . Under such optimal conditions of "antigen" presentation, T cells produce high quantities of lymphokines, including interferon y and IL-4 (23). This lymphokine response is first detected three days after the injection of the goat anti-IgD (22) (23) (24) and is therefore unlikely to be responsible for the early phase of TS-cell induction, which is maximal within 24 hr after treatment (Fig. 1) . However, since previous studies have established that certain lymphokines such as IL-2, interferon y (5), and IL-4 (25) can also induce TS cells, it is possible that the continued presence of increased numbers of TS cells observed beyond day 3 is attributable to the stimulatory effect of such factors. (Table 3) (13) . The results in Table 4 show that whereas the Hba/1 Fab/Fc was active in inducing TS cells when injected by itself into BALB/c mice, simultaneous injection of Hba/1 Fab/Fc and 2.4G2 failed to induce TS cells. The 2.4G2 antibody, which does not prevent IgD crosslinking or B-cell activation by intact Hba/1, also had no effect on the ability of the intact H~a/1 antibody to induce TS cells in vivo. We conclude that receptors on T cells, we utilized the B-cell lymphoma CH15, which coexpresses IgD and IgM (10). Our experimental approach was to coculture T cells isolated from BMO.A mice with CH15 cells that had been preincubated with antibodies to their surface immunoglobulin and then fixed with paraformaldehyde (26) . Under these conditions, we showed by immunofluorescent staining methods (using fluoresceinlabeled anti-goat immunoglobulin and indirect staining for surface IgD) that the anti-immunoglobulin antibodies re- 4.2 ± 0.7 Groups of three mice were injected i.v. on day -1 with Hba/1 (100 jLg), H8a/1 Fab/Fc (100 ,.g), 2 .4G2 (500 pug), or a combination of the above. Splenic T cells were prepared on day 0, and the IgD-RFC assay was performed. mained bound to the surface of the lymphoma cells following a 24-hr culture period (data not shown). The results in Table  5 demonstrate that when T cells were cultured for 24 hr with either anti-immunoglobulin (heavy and light chain) or antiIgD-treated, paraformaldehyde-fixed CH15 cells a significant increase in the frequency of TS cells was observed. In contrast, CH15 cells preteated with an anti-IgM had no effect on the expression of IgD receptors on T cells and neither did CH15 cells treated with paraformaldehyde alone. These results indicate that crosslinking of surface IgD, but not surface IgM, under (27, 28) . Such downregulation results in the disappearance of IgD from the B-cell surface within a few days of activation with antigen (28) . Indeed, these findings are consistent with the concept that IgD is primarily a receptor molecule, which, unlike other immunoglobulins, is not secreted following triggering of B cells expressing the 8 heavy chain.
The relative role of induction of TS cells in the stimulation of polyclonal immunoglobulin production, which occurs after injection of anti-IgD antibody, appears to be minor as compared to the combination of (i) the direct activating effect of anti-IgD antibody on B cells and (it) the presentation to T cells of the allo-or xenogeneic determinants on anti-IgD antibodies that are bound to and processed by B cells and that stimulate T-cell activation and lymphokine production (20, 23, 24) . This is suggested by the comparison of our present results on the induction of TS cells with the results of Finkelman et al. (20) . In all cases where the polyclonal activation of IgG production is induced by injection of anti-IgD, TS cells are also induced. However, in experiments in which allotype-specific anti-IgD is injected into (a x b)F1 hybrid mice, TS cells can be induced without the marked activation of polyclonal immunoglobulin production seen when the allotypic anti-IgD is antigenic for the mice into which it is injected (20) . Thus, whereas enhancement of antibody production to a totally unrelated antigen is produced by simultaneous injection or pretreatment with syngeneic IgD (2), injection of anti-IgD primarily enhances the immune response to haptens bound to the anti-IgD or to epitopes of the anti-IgD itself if the anti-IgD antibody is foreign and thus itself immunogenic (20, 29) . In view of the TS-mediated immunoaugmenting effect of TEPC-1017 IgD, it is not immediately clear why the response to simultaneously injected unrelated antigens is not always augmented by TS cells induced by allotypic or goat anti-IgD. It seems possible that the large excess of anti-IgD used in these experiments causes such a rapid down-regulation of surface IgD expression that the augmenting effect of TS cells on antibody production is prevented by the absence of IgD-antigen complexes. However, a less impressive but definite effect on antibody formation to unrelated antigens has been obtained in (a x b)F1 hybrids with nonimmunogenic allotypic antiIgD (30) . In the absence of additional lymphokine injections, this effect is limited to the allotype not affected by the anti-IgD (30) and may be a consequence of TS-cell induction. Although TS cells are clearly not allotype specific (1), they apparently augment the responses of those B cells that express surface IgD interacting with antigen more than the response by B cells that have had their surface IgD downmodulated by the anti-IgD.
